AbbVie moves Rinvoq into phase 3 for lupus
Michael Vi/iStock Editorial via Getty Images
- Following positive phase 2 results, AbbVie (NYSE:ABBV) is advancing its JAK inhibitor Rinvoq into phase 3 (upadacitinib) for systemic lupus erythematosus.
- The mid-stage data showed that Rinvoq either alone or in combination with Bruton's Tyrosine Kinase inhibitor elsubrutinib met its primary endpoint. The combination is known as ABBV-599.
- The endpoint was SLE Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in the Rinvoq 30 mg group.
- There were no new safety signals reported.
- Rinvoq is already approved for other auto-immune conditions, including eczema, rheumatoid arthritis, and psoriatic arthritis.
- Read why Seeking Alpha contributor Value Prof rates AbbVie (ABBV) a buy.